CXCL8/CXCR2 signaling mediates bone marrow fibrosis and represents a therapeutic target in myelofibrosis
Blood · 2023
DOI: 10.1182/blood.2022015418 ↗Kurz gefasst
Fachartikel in der Zeitschrift Blood, 2023. Verfasst von Andrew J Dunbar und 38 weiteren Autor:innen. Beteiligte Einrichtung: Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY. Hauptthemen laut MEDLINE: Primary Myelofibrosis, Myeloproliferative Disorders, Neoplasms. Die Arbeit wurde bisher 25-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIBIB NIH HHS.
Abstract (Originalsprache)
Pro-inflammatory signaling is a hallmark feature of human cancer, including in myeloproliferative neoplasms (MPNs), most notably myelofibrosis (MF). Dysregulated inflammatory signaling contributes to fibrotic progression in MF; however, the individual cytokine mediators elicited by malignant MPN cells to promote collagen-producing fibrosis and disease evolution remain yet to be fully elucidated. Previously we identified a critical role for combined constitutive JAK/STAT and aberrant NF-kB pro-inflammatory signaling in myelofibrosis development. Using single-cell transcriptional and cytokine-secretion studies of primary MF patient cells and the hMPLW515L murine model of myelofibrosis, we extend this previous work and delineate the role of CXCL8/CXCR2 signaling in MF pathogenesis and bone marrow fibrosis progression. MF patient hematopoietic stem/progenitor cells are enriched for a CXCL8/CXCR2 gene signature and display enhanced proliferation and fitness in response to exogenous CXCL8 ligand in vitro. Genetic deletion of Cxcr2 in the hMPLW515L adoptive transfer model abrogates fibrosis and extends overall survival, and pharmacologic inhibition of the CXCR1/2 pathway improves hematologic parameters, attenuates bone marrow fibrosis, and synergizes with JAK inhibitor therapy. Our mechanistic insights provide a rationale for therapeutic targeting of the CXCL8/CXCR2 pathway in MF patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY.
- Leukemia Service, Department of Medicine and Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY.
- Myeloproliferative Neoplasm-Research Consortium, Icahn School of Medicine at Mount Sinai, New York, NY.
- Department of Biomedical Engineering, Yale University, New Haven, CT.
- Division of Hematology/Oncology, Tisch Cancer Institute and Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY.
- Blood Diseases and Bone Marrow Transplantation Unit, Cell Therapies and Hematology Research Program, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
ORCID-Profile: Mirko Farina, Robert L Bowman, Julie L Yang, Wenbin Xiao, Francesca Gobbo, Fabrizio Martelli, Giuseppe Sarli, Yang Xiao, Erin McGovern, Jenna Snyder, Aishwarya Krishnan, Corrine Hill, Eric Tucker, Jonathan Chen, Anna R Migliaccio, Rong Fan
Förderung
- NCI NIH HHS
- NIBIB NIH HHS
Zitieren
APA
Dunbar, A. J., Kim, D., Lu, M., Farina, M., Bowman, R. L., Yang, J. L., Park, Y., Karzai, A., Xiao, W., Zaroogian, Z., O'Connor, K., Mowla, S., Gobbo, F., Verachi, P., Martelli, F., Sarli, G., Xia, L., Elmansy, N., Kleppe, M., …, & Hoffman, R. (2023). CXCL8/CXCR2 signaling mediates bone marrow fibrosis and represents a therapeutic target in myelofibrosis. Blood. https://doi.org/10.1182/blood.2022015418
Vancouver
Dunbar AJ, Kim D, Lu M, Farina M, Bowman RL, Yang JL, et al. CXCL8/CXCR2 signaling mediates bone marrow fibrosis and represents a therapeutic target in myelofibrosis. Blood. 2023. doi:10.1182/blood.2022015418
BibTeX
@article{Dunbar2023,
author = {Dunbar, Andrew J and Kim, Dongjoo and Lu, Min and Farina, Mirko and Bowman, Robert L and Yang, Julie L and Park, Young and Karzai, Abdul and Xiao, Wenbin and Zaroogian, Zach and O'Connor, Kavi and Mowla, Shoron and Gobbo, Francesca and Verachi, Paola and Martelli, Fabrizio and Sarli, Giuseppe and Xia, Lijuan and Elmansy, Nada and Kleppe, Maria and Chen, Zhuo and Xiao, Yang and McGovern, Erin and Snyder, Jenna and Krishnan, Aishwarya and Hill, Corrine and Cordner, Keith and Zouak, Anouar and Salama, Mohamed E and Yohai, Jayden and Tucker, Eric and Chen, Jonathan and Zhou, Jing and McConnell, Timothy and Migliaccio, Anna R and Koche, Richard and Rampal, Raajit and Fan, Rong and Levine, Ross L and Hoffman, Ronald},
title = {CXCL8/CXCR2 signaling mediates bone marrow fibrosis and represents a therapeutic target in myelofibrosis},
journal = {Blood},
year = {2023},
doi = {10.1182/blood.2022015418}
}
EUVIMED